Health care professionals are being warned about the risk for dosing errors with the antibacterial drug Zerbaxa, because of confusion about the drug strength displayed on the vial and carton labeling.
Zerbaxa’s vial label was initially approved with a strength that reflects each individual active ingredient, however the product is dosed based on the sum of these ingredients, according to the FDA.
In some cases, this led to administration of 50% more drug than was prescribed. No adverse events were reported among these seven cases, the FDA reported.
To prevent future medication errors, the strength on the drug labeling has been revised to reflect the sum of the two active ingredients.
